Watch EDVA. Know when insiders buy.
One email the day a filing lands. Free.
EDVA
Endovia Health Sciences, Inc.
0.25
+0.00 +2.05%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.6MP/E —DIV YIELD —FCF YIELD —REV TTM $32K −101.8%NET INCOME −$17.3MNET CASH $242K52W 0.24 – 10.16SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$2M | −$2.1M | — | — | −$1.1M | — | — | Aug 19 |
| Q1 2026 · Mar 31 | $4K | −93.8% | 43.8% | −$979K | −$2.1M | — | -0.47 | −$930K | — | — | Aug 19 |
| Q4 2025 · Dec 31derived | −$365K | — | -13.0% | −$976K | −$3.2M | — | — | −$991K | — | — | Apr 15 |
| Q3 2025 · Sep 30 | $393K | −60.0% | -6.1% | −$9.5M | −$9.9M | — | — | −$2.5M | — | — | Nov 19 |
| Q2 2025 · Jun 30 | −$23K | −102.2% | 137.3% | −$1.5M | −$8.5M | — | — | −$551K | — | — | Aug 19 |
| Q1 2025 · Mar 31 | $69K | −95.5% | 37.2% | −$1.7M | −$3.7M | — | -1.97 | −$808K | — | — | Aug 19 |
| Q4 2024 · Dec 31derived | −$2.8M | −203.0% | 29.6% | −$290K | −$9M | — | — | −$920K | $0 | −$920K | Apr 15 |
| Q3 2024 · Sep 30 | $982K | −80.9% | 29.6% | −$2.7M | −$4.7M | — | — | −$2.6M | — | — | Nov 19 |
| Q2 2024 · Jun 30 | $1M | — | 23.4% | −$3.7M | −$5.3M | — | — | −$2.4M | — | — | Nov 19 |
| Q1 2024 · Mar 31 | $1.5M | — | 10.6% | −$3.3M | −$4.7M | — | — | −$1.3M | $0 | −$1.3M | Nov 19 |
| Q4 2023 · Dec 31derived | $2.7M | — | 27.3% | −$3.3M | −$6M | — | — | −$1.7M | $2K | −$1.7M | Jul 11 |
| Q3 2023 · Sep 30 | $5.1M | — | 25.2% | −$4.3M | −$5.7M | — | -0.13 | −$2M | $0 | −$2M | Nov 15 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $73K | 23.1% | −$14.2M | −$25.2M | -34537.0% | -11.97 | −$4.8M | — | — | — | — |
| FY2024 · to Dec 31 | $801K | -15.0% | −$9.9M | −$23.8M | -2964.9% | -17.68 | −$7.3M | $3K | −$7.3M | — | — |
| FY2023 · to Dec 31 | $18.9M | 29.5% | −$15.3M | −$21M | -111.4% | — | −$10.2M | $14K | −$10.2M | — | — |
| FY2022 · to Dec 31 | $18.1M | 32.7% | −$21.4M | −$21.7M | -119.9% | — | −$14M | $103K | −$14.1M | — | — |
| FY2021 · to Dec 31 | $11.3M | 34.6% | −$29.1M | −$29.1M | -256.7% | -1.02 | −$14.7M | $0 | −$14.7M | — | — |
| FY2020 · to Dec 31 | $2.3M | 15.8% | −$17.7M | −$28.7M | -1246.7% | -1.06 | −$21.3M | $91K | −$21.4M | — | — |
Every number comes from Endovia Health Sciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.